Allakos (ALLK) News Today $1.20 -0.09 (-6.98%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Kuehn Law Encourages Investors of Allakos Inc. to Contact Law FirmDecember 19 at 4:15 PM | prnewswire.comPromising Potential of Allakos’s AK006 Drives Buy Rating Amidst Market Interest in Chronic Spontaneous UrticariaDecember 17, 2024 | markets.businessinsider.comFmr LLC Increases Stock Holdings in Allakos Inc. (NASDAQ:ALLK)Fmr LLC lifted its stake in Allakos Inc. (NASDAQ:ALLK - Free Report) by 14.6% in the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 5,370,247 shares of the company's stock after purchasing an additional 685,623 shares during the quarter. Fmr LLC oDecember 14, 2024 | marketbeat.comPoint72 Asset Management L.P. Purchases New Position in Allakos Inc. (NASDAQ:ALLK)Point72 Asset Management L.P. acquired a new stake in shares of Allakos Inc. (NASDAQ:ALLK - Free Report) in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 1,750,000 shares of the company's stock, valued at aDecember 11, 2024 | marketbeat.comKuehn Law Encourages Investors of Allakos Inc. to Contact Law FirmDecember 9, 2024 | markets.businessinsider.comAllakos Reports Q3 2024 Results and Research ProgressNovember 22, 2024 | markets.businessinsider.comAllakos Inc. Alters Lease Agreement for Cost SavingsNovember 19, 2024 | markets.businessinsider.comLeerink Partnrs Increases Earnings Estimates for AllakosAllakos Inc. (NASDAQ:ALLK - Free Report) - Leerink Partnrs upped their FY2024 earnings estimates for Allakos in a note issued to investors on Thursday, November 7th. Leerink Partnrs analyst T. Smith now forecasts that the company will earn ($1.19) per share for the year, up from their prior estimNovember 11, 2024 | marketbeat.comAllakos (ALLK) Gets a Hold from TD CowenNovember 8, 2024 | markets.businessinsider.comAllakos (ALLK) Gets a Sell from BarclaysNovember 8, 2024 | markets.businessinsider.comAllakos Runs Up Into A Near-Term CatalystNovember 7, 2024 | seekingalpha.comAllakos Provides Business Update and Reports Third Quarter 2024 Financial ResultsNovember 6, 2024 | globenewswire.comAllakos Inc. (NASDAQ:ALLK) Short Interest Down 17.1% in OctoberAllakos Inc. (NASDAQ:ALLK - Get Free Report) was the target of a significant drop in short interest in the month of October. As of October 15th, there was short interest totalling 1,650,000 shares, a drop of 17.1% from the September 30th total of 1,990,000 shares. Based on an average trading volume of 547,900 shares, the short-interest ratio is currently 3.0 days.October 28, 2024 | marketbeat.comAllakos (NASDAQ:ALLK) Stock Quotes, Forecast and News SummaryOctober 24, 2024 | benzinga.comAnalysts Conflicted on These Healthcare Names: Allakos (ALLK), Edwards Lifesciences (EW) and NewAmsterdam Pharma Company (NAMS)October 14, 2024 | markets.businessinsider.comPiper Sandler Sticks to Its Buy Rating for Allakos (ALLK)October 13, 2024 | markets.businessinsider.comAllakos Inc.: Allakos Announces Phase 1 Trial Results of Subcutaneous AK006 in Healthy VolunteersOctober 12, 2024 | finanznachrichten.deLifeSci Capital Reaffirms Their Hold Rating on Allakos (ALLK)October 12, 2024 | markets.businessinsider.comTD Cowen Sticks to Their Hold Rating for Allakos (ALLK)October 12, 2024 | markets.businessinsider.comAllakos perks up after early-stage data for lead assetOctober 12, 2024 | msn.comAllakos Announces Phase 1 Trial Results of Subcutaneous AK006 in Healthy VolunteersOctober 10, 2024 | globenewswire.comThird Harmonic Bio: Nothing Stands OutOctober 7, 2024 | seekingalpha.comAllakos’s AK006 Poised for Strategic Advantage in CSU Market: A ‘Buy’ RecommendationSeptember 26, 2024 | markets.businessinsider.comAllakos Inc. (NASDAQ:ALLK) Sees Significant Drop in Short InterestAllakos Inc. (NASDAQ:ALLK - Get Free Report) was the recipient of a significant decline in short interest in the month of August. As of August 31st, there was short interest totalling 1,940,000 shares, a decline of 16.0% from the August 15th total of 2,310,000 shares. Based on an average daily trading volume, of 554,000 shares, the days-to-cover ratio is currently 3.5 days.September 16, 2024 | marketbeat.comAllakos (NASDAQ:ALLK) Trading 2.1% Higher Allakos (NASDAQ:ALLK) Stock Price Up 2.1%September 10, 2024 | marketbeat.comPrice T Rowe Associates Inc. MD Lowers Holdings in Allakos Inc. (NASDAQ:ALLK)Price T Rowe Associates Inc. MD cut its holdings in Allakos Inc. (NASDAQ:ALLK - Free Report) by 91.9% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 638,102 shares of the company's stockAugust 13, 2024 | marketbeat.comEquities Analysts Issue Forecasts for Allakos Inc.'s FY2024 Earnings (NASDAQ:ALLK)Allakos Inc. (NASDAQ:ALLK - Free Report) - Stock analysts at Leerink Partnrs boosted their FY2024 earnings estimates for Allakos in a research note issued on Thursday, August 8th. Leerink Partnrs analyst T. Smith now expects that the company will post earnings per share of ($1.24) for the year, uAugust 12, 2024 | marketbeat.comAllakos Inc. (ALLK) stock historical prices & data – Yahoo FinanceAugust 11, 2024 | au.finance.yahoo.comMaintaining Hold on Allakos: Weighing AK006 Promise Against Clinical SetbacksAugust 9, 2024 | markets.businessinsider.comAllakos (NASDAQ:ALLK) Posts Quarterly Earnings Results, Beats Estimates By $0.02 EPSAllakos (NASDAQ:ALLK - Get Free Report) released its quarterly earnings data on Wednesday. The company reported ($0.30) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.32) by $0.02.August 8, 2024 | marketbeat.comHold Rating on Allakos Amid Uncertainty Over AK006’s Clinical Efficacy and Financial HealthAugust 8, 2024 | markets.businessinsider.comAllakos Provides Business Update and Reports Second Quarter 2024 Financial ResultsAugust 7, 2024 | globenewswire.comAllakos Inc. (NASDAQ:ALLK) Stock Holdings Lifted by Acadian Asset Management LLCAcadian Asset Management LLC lifted its position in Allakos Inc. (NASDAQ:ALLK - Free Report) by 1,753.1% in the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 1,331,639 shares of the company's stock after acquiring an additional 1,259July 25, 2024 | marketbeat.comCan Allakos (NASDAQ:ALLK) Afford To Invest In Growth?July 23, 2024 | finance.yahoo.comAllakos (NASDAQ:ALLK) PT Lowered to $1.00Jefferies Financial Group cut their price objective on Allakos from $1.50 to $1.00 and set a "hold" rating for the company in a report on Thursday.July 18, 2024 | marketbeat.comAllakos Inc. (NASDAQ:ALLK) Short Interest Down 6.7% in JuneAllakos Inc. (NASDAQ:ALLK - Get Free Report) saw a large decline in short interest in June. As of June 30th, there was short interest totalling 4,740,000 shares, a decline of 6.7% from the June 15th total of 5,080,000 shares. Based on an average daily volume of 616,300 shares, the short-interest ratio is presently 7.7 days.July 16, 2024 | marketbeat.comAllakos Inc. (NASDAQ:ALLK) CFO Sells $87,934.64 in StockJuly 3, 2024 | insidertrades.comAllakos Inc. (NASDAQ:ALLK) CFO Harlan Baird Radford Sells 87,064 SharesAllakos Inc. (NASDAQ:ALLK - Get Free Report) CFO Harlan Baird Radford sold 87,064 shares of the firm's stock in a transaction dated Friday, June 28th. The stock was sold at an average price of $1.01, for a total value of $87,934.64. Following the transaction, the chief financial officer now directly owns 204,390 shares in the company, valued at approximately $206,433.90. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.July 2, 2024 | marketbeat.comAllakos (NASDAQ:ALLK) Given Market Outperform Rating at JMP SecuritiesJMP Securities reissued a "market outperform" rating and set a $3.00 price target on shares of Allakos in a research report on Wednesday.June 26, 2024 | marketbeat.comAllakos Announces Positive Results from its Ongoing Phase 1 Trial of AK006 in Healthy Volunteers, with AK006 Demonstrating High Receptor Occupancy on Mast Cells and a Favorable Safety ProfileJune 25, 2024 | globenewswire.comAllakos (NASDAQ:ALLK) Earns Neutral Rating from Cantor FitzgeraldCantor Fitzgerald reiterated a "neutral" rating on shares of Allakos in a research note on Thursday.June 20, 2024 | marketbeat.comAllakos Inc.: Allakos Announces First Patient Dosed in Phase 1 Trial of AK006 in Chronic Spontaneous UrticariaMay 29, 2024 | finanznachrichten.deAllakos Announces First Patient Dosed in Phase 1 Trial of AK006 in Chronic Spontaneous UrticariaMay 28, 2024 | globenewswire.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: ARS Pharmaceuticals (SPRY), AnaptysBio (ANAB) and Allakos (ALLK)May 15, 2024 | markets.businessinsider.comAllakos (NASDAQ:ALLK) Trading Down 7%Allakos (NASDAQ:ALLK) Shares Down 7%May 11, 2024 | marketbeat.comAllakos Inc.: Allakos Provides Business Update and Reports First Quarter 2024 Financial ResultsMay 10, 2024 | finanznachrichten.deAllakos Inc. Reports Increased Losses in Q1 2024, Misses Analyst Earnings PredictionsMay 10, 2024 | finance.yahoo.comAllakos Buy Rating: Clinical Promise and Financial Stability Drive Positive OutlookMay 10, 2024 | markets.businessinsider.comALLK Stock Earnings: Allakos Meets EPS for Q1 2024May 9, 2024 | investorplace.comAllakos Provides Business Update and Reports First Quarter 2024 Financial ResultsMay 9, 2024 | globenewswire.com Get Allakos News Delivered to You Automatically Sign up to receive the latest news and ratings for ALLK and its competitors with MarketBeat's FREE daily newsletter. Email Address URGENT: This Altcoin Opportunity Won’t Wait – Act Now (Ad)Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight. >> Register for the Workshop Now ALLK Media Mentions By Week ALLK Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ALLK News Sentiment▼0.820.59▲Average Medical News Sentiment ALLK News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ALLK Articles This Week▼21▲ALLK Articles Average Week Get Allakos News Delivered to You Automatically Sign up to receive the latest news and ratings for ALLK and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Cryoport News Today Olema Pharmaceuticals News Today Procaps Group News Today Design Therapeutics News Today Neurogene News Today Contineum Therapeutics News Today Acelyrin News Today Rigel Pharmaceuticals News Today Tango Therapeutics News Today Kamada News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ALLK) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Allakos Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Allakos With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ALLK Stock Alerts